<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406418</url>
  </required_header>
  <id_info>
    <org_study_id>FLU-M6-C001</org_study_id>
    <secondary_id>DMID Protocol 11-0025</secondary_id>
    <nct_id>NCT01406418</nct_id>
  </id_info>
  <brief_title>Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR6261, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose Intravenous Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess in healthy subjects the safety, tolerability,&#xD;
      pharmacokinetics and immunogenicity of single escalating doses of CR6261, a monoclonal&#xD;
      antibody against influenza A viruses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, placebo-controlled dose escalation study will enroll up to 6&#xD;
      cohorts of healthy subjects. Eight subjects will be enrolled in each cohort (1 to 5) and will&#xD;
      receive a single 2-hour intravenous infusion of CR6261 (6 subjects) or placebo (2 subjects)&#xD;
      on Day 1. Subjects will be dosed in pairs of two. Once all subjects in a cohort have&#xD;
      completed Study Day 8, the preliminary safety data will be reviewed. Provided that no safety&#xD;
      issues are identified, dose escalation to the subsequent cohort may be permitted.&#xD;
&#xD;
      To obtain additional data at the 30 mg/kg dose level, a sixth cohort will be enrolled after&#xD;
      the preliminary safety and tolerability of the 30 mg/kg dose in Cohort 4 is demonstrated.&#xD;
      Cohort 6 will be comprised of 24 subjects (randomized 5 : 1 to CR6261 or placebo) following&#xD;
      the same visit schedule as subjects in Cohorts 1-5.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and changes in laboratory parameters and vital signs as measures of safety and tolerability of single escalating doses of CR6261</measure>
    <time_frame>From baseline to 75 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetics of single escalating doses of CR6261</measure>
    <time_frame>From baseline to 75 days post-dose</time_frame>
    <description>Pharmacokinetic parameters include area under the serum concentration-time curve from zero to the time of the last measurable concentration (AUC0-t), area under the serum concentration-time curve from zero to infinity (AUC0-inf), maximum concentration (Cmax), time of Cmax (tmax), systemic clearance (CL), terminal elimination half life (t1/2), etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of antibodies binding to CR6261 as a measure of immunogenicity of single escalating doses of CR6261</measure>
    <time_frame>From baseline to 75 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1: CR6261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg CR6261</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose in water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: CR6261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg CR6261</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose in water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: CR6261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg CR6261</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose in water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: CR6261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg/kg CR6261</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose in water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: CR6261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg/kg CR6261</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose in water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: CR6261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg/kg CR6261</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose in water</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR6261 2 mg/kg</intervention_name>
    <description>Administered as a single 2-hour intravenous infusion</description>
    <arm_group_label>Cohort 1: CR6261</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR6261 5 mg/kg</intervention_name>
    <description>Administered as a single 2-hour intravenous infusion</description>
    <arm_group_label>Cohort 2: CR6261</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR6261 15 mg/kg</intervention_name>
    <description>Administered as a single 2-hour intravenous infusion</description>
    <arm_group_label>Cohort 3: CR6261</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR6261 30 mg/kg</intervention_name>
    <description>Administered as a single 2-hour intravenous infusion</description>
    <arm_group_label>Cohort 4: CR6261</arm_group_label>
    <arm_group_label>Cohort 6: CR6261</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR6261 50 mg/kg</intervention_name>
    <description>Administered as a single 2-hour intravenous infusion</description>
    <arm_group_label>Cohort 5: CR6261</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as a single 2-hour intravenous infusion</description>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <arm_group_label>Cohort 5: Placebo</arm_group_label>
    <arm_group_label>Cohort 6 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Adult male and female subjects aged 18 to 50 years on Study Day 1.&#xD;
&#xD;
          2. Body mass index between 18 and 30 (kg/m2) by nomogram or calculation; body weight&#xD;
             between 50 kg and 100 kg.&#xD;
&#xD;
          3. Has acceptable blood pressure and heart rate parameters within the normal limits&#xD;
             (systolic = 88-140 mmHg; diastolic = 50 to &lt;90 mmHg; heart rate = 46 to 100 bpm).&#xD;
&#xD;
          4. Healthy as determined by pre-study medical history, physical examination, and&#xD;
             laboratory assessments.&#xD;
&#xD;
          5. Able and willing to give written informed consent.&#xD;
&#xD;
          6. Has the ability to complete the follow-up period of 75 days as required by the&#xD;
             protocol.&#xD;
&#xD;
          7. Subjects must agree to abstain from alcohol intake 24 hours before administration of&#xD;
             study drug, during the inpatient period of the study and 24 hours prior to all other&#xD;
             outpatient clinic visits.&#xD;
&#xD;
          8. Subjects must agree to not use OTC medications (including aspirin, decongestants,&#xD;
             antihistamines and other NSAIDs), and herbal medication (including, but not limited&#xD;
             to, herbal tea, St. John's Wort), within 14 days prior to study drug administration&#xD;
             through the final follow-up visit, unless approved by the investigator and medical&#xD;
             monitor. Occasional use of acetaminophen/paracetamol at recommended doses (≤ 1 gram/6&#xD;
             hours and ≤ 4 grams/day) and continued pre-existing use of vitamins or multivitamins&#xD;
             at recommended doses is allowed.&#xD;
&#xD;
          9. Female subjects must:&#xD;
&#xD;
               -  Be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal&#xD;
                  ligation, or otherwise be incapable of pregnancy), or&#xD;
&#xD;
               -  If heterosexually active, use two effective methods of birth control, including&#xD;
                  hormonal prescription oral contraceptives, contraceptive injections,&#xD;
                  contraceptive patch, contraceptive ring, intrauterine device, barrier method&#xD;
                  (e.g. condoms, diaphragm, or cervical cap), or spermicidal foam, cream, or gel),&#xD;
                  or&#xD;
&#xD;
               -  Confirm male partner sterilization, or&#xD;
&#xD;
               -  Not be heterosexually active Note: women who are not heterosexually active at&#xD;
                  screening must agree to utilize two effective methods of birth control if they&#xD;
                  become heterosexually active during their participation in the study.&#xD;
&#xD;
             Women must agree to continue using these methods of contraception throughout the&#xD;
             study.&#xD;
&#xD;
         10. Females must have a negative urine pregnancy test at both screening and baseline.&#xD;
&#xD;
         11. If a man who is able to father a child and sexually active with a female of&#xD;
             childbearing potential, he must agree to use a double barrier method of birth control&#xD;
             (e.g. condom with spermicidal foam, cream, or gel) and to not donate sperm during the&#xD;
             study.&#xD;
&#xD;
         12. Subjects must agree to avoid strenuous exercise (e.g. long distance running &gt;5 km/day,&#xD;
             weight lifting, or any physical activity to which the subject is not accustomed) while&#xD;
             confined to the Clinical Unit and for at least 72 hours prior to study drug&#xD;
             administration and follow up visits.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Acute illness at the time of entry into the study (Study Day 1).&#xD;
&#xD;
          2. Temperature &gt;99.5oF (37.5oC) at randomization.&#xD;
&#xD;
          3. Presence of a significant infection or known inflammatory process during screening or&#xD;
             at the time of randomization.&#xD;
&#xD;
          4. Presence of acute gastrointestinal symptoms during screening or at the time of&#xD;
             randomization (e.g. nausea, vomiting, diarrhea, or heartburn).&#xD;
&#xD;
          5. A diagnosis of influenza infection or any constellation of clinical symptoms&#xD;
             consistent with influenza infection (e.g. fever, myalgias, headache, fatigue,&#xD;
             non-productive cough, sore throat, and/or rhinorrhea) within 14 days prior to Study&#xD;
             Day 1.&#xD;
&#xD;
          6. Received any live virus or bacterial vaccinations within 3 months prior to screening&#xD;
             or are expected to receive any live virus or bacterial vaccinations during the study.&#xD;
&#xD;
          7. Received inactivated influenza vaccines within 2 weeks of Study Day 1 or are expected&#xD;
             to receive an inactivated influenza vaccine during the study.&#xD;
&#xD;
          8. Any chronic condition requiring prescription or over-the-counter medicine, with the&#xD;
             exception of vitamins.&#xD;
&#xD;
          9. Chronic (longer than 14 days) administration of immunosuppressants or other immune&#xD;
             modifying drugs within 6 months before administration of the investigational product;&#xD;
             oral corticosteroids in dosages of &lt; 0.5 mg/kg/d prednisolone or equivalent and&#xD;
             inhaled/nasally/topically administered corticosteroids are permitted.&#xD;
&#xD;
         10. Antibiotic therapy within 7 days before Study Day 1.&#xD;
&#xD;
         11. History and/or presence of any clinically significant disease or disorder such as&#xD;
             cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and&#xD;
             psychiatric/mental disease/disorders, which, in the opinion of the Principal&#xD;
             Investigator may either put the subject at risk because of participation in the study,&#xD;
             influence the results of the study or the subject's ability to participate in the&#xD;
             study.&#xD;
&#xD;
         12. Previous medical history that may compromise the safety of the subject in the study.&#xD;
&#xD;
         13. Positive serology for the human immunodeficiency virus (HIV) 1 or 2 antibody,&#xD;
             hepatitis C virus antibody or hepatitis B surface antigen.&#xD;
&#xD;
         14. History of a previous severe allergic reaction with generalized urticaria, angioedema,&#xD;
             or anaphylaxis.&#xD;
&#xD;
         15. Known or suspected hypersensitivity to any CR6261 excipients (Sucrose, L-Histidine&#xD;
             L-Histidine Monohydrochloride, Polysorbate 20).&#xD;
&#xD;
         16. A history of alcohol or drug abuse within the past 2 years as according to DSM IV.&#xD;
&#xD;
         17. Positive urine test for illicit drugs (opiates, cocaine, amphetamines) during&#xD;
             screening and admission (Day -1).&#xD;
&#xD;
         18. Subjects who report current tobacco use of more than 10 cigarettes or 2 cigars per day&#xD;
             at screening or anticipate use exceeding this amount at any time during the study.&#xD;
&#xD;
         19. Receipt of any other investigational product within 1 month or 5 half-lives (whichever&#xD;
             is longer) before administration of the study investigational product.&#xD;
&#xD;
         20. Participation in any clinical study involving receipt of investigational product,&#xD;
             blood or blood products, or donation of blood throughout the duration of the study.&#xD;
&#xD;
         21. Received antibody or biologic therapy (e.g. Ig products, mAbs, or antibody fragments).&#xD;
&#xD;
         22. Subjects who have donated and/or received any blood or blood products within 3 months&#xD;
             before administration of the study investigational product or planned donation/receipt&#xD;
             throughout the course of the study.&#xD;
&#xD;
         23. Subjects who cannot communicate reliably with the investigator.&#xD;
&#xD;
         24. Any condition that in the opinion of the investigator would complicate or compromise&#xD;
             the study, or the well being of the subject.&#xD;
&#xD;
         25. Employee at the clinic, or spouse/relative of the investigator or employees.&#xD;
&#xD;
         26. Has experienced an anaphylactic reaction to latex.&#xD;
&#xD;
         27. Have currently or a past history of thrombocytopenia or bleeding abnormality.&#xD;
&#xD;
         28. Is unable or unwilling to undergo multiple venipunctures because of poor tolerability&#xD;
             or lack of easy access to veins.&#xD;
&#xD;
         29. Female subjects who are breastfeeding.&#xD;
&#xD;
         30. Drinks more than 1200 mL (or 5 cups of 240 mL per cup) of tea/coffee/cocoa/cola or&#xD;
             other caffeinated beverage per day more than one day per week in the 2 weeks before&#xD;
             screening.&#xD;
&#xD;
         31. ECG findings (Screening or Day-1):&#xD;
&#xD;
               -  QTc interval &gt;450 msec;&#xD;
&#xD;
               -  evidence of second- or third-degree atrioventricular (AV) block;&#xD;
&#xD;
               -  pathological Q-waves (defined as Q-wave &gt;40 msec or depth greater than 0.4 - 0.5&#xD;
                  mV);&#xD;
&#xD;
               -  evidence of ventricular pre-excitation;&#xD;
&#xD;
               -  electrocardiographic evidence of complete left bundle branch block, right bundle&#xD;
                  branch block (RBBB), incomplete LBBB;&#xD;
&#xD;
               -  intraventricular conduction delay with QRS duration &gt;120 msec.&#xD;
&#xD;
         32. Laboratory assessments (Screening or Day -1):&#xD;
&#xD;
               -  Hemoglobin below the lower limit of normal (LLN); a lower limit of 13.6 g/dL in&#xD;
                  males is acceptable;&#xD;
&#xD;
               -  Platelet count, absolute neutrophil count (ANC), or absolute lymphocyte count&#xD;
                  below LLN (ANC of 1.3 x 10³/µL is acceptable lower limit for African Americans);&#xD;
&#xD;
               -  White blood cell count above the upper limit of normal (ULN) or below the LLN&#xD;
                  (3.2 x 10³/µL is acceptable lower limit for African Americans);&#xD;
&#xD;
               -  Creatinine above the ULN;&#xD;
&#xD;
               -  PT or PTT above the ULN;&#xD;
&#xD;
               -  ALT, AST, GGTP, ALP, amylase, lipase, or total bilirubin ≥ 1.1 times the ULN&#xD;
                  (values below the LLN are not considered clinically significant).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleanor Lisbon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Early Clinical Development</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Virus</keyword>
  <keyword>Monoclonal</keyword>
  <keyword>Antibody</keyword>
  <keyword>Immunization</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

